Breakthrough Pancreatic Cancer Drug Illustrates Importance of Research

Breakthrough pancreatic cancer drug illustrates importance of research

Open the article to view the coverage from Chicago Sun Times

Letters: Breakthrough cancer drugs of tomorrow depend on investment today

For decades, pancreatic cancer has remained one of the most difficult cancers to treat. Most patients are diagnosed at an advanced stage, when surgery is no longer an option, and for those whose cancer has worsened despite chemotherapy, treatment options…

Pancreatic cancer drug helping former U.S. Sen. Ben Sasse now offered locally

Nebraska Cancer Specialists and the Fred & Pamela Buffett Cancer Center are participating in a expanded access program that allows them to offer a new pancreatic cancer drug to patients while it is under review by the FDA.

When 10,000 doctors stood up and cheered for a cancer drug — America's innovation machine made it possible

Daraxonrasib nearly doubled pancreatic cancer survival to 13.2 months — but the IRA's "Pill Penalty" threatens the system that produced it.

Breakthrough pancreatic cancer drug nearly doubles survival in trial

By Janet Loehrke – USA Today A new experimental drug may offer hope for pancreatic cancer patients. One of deadliest types of cancer in the United States, an estimated 52,740 Americanswill die from the disease this year, according to the American Cancer Society. Patients who received the drug lived a median of 13.2 months, compared with 6.7 months for those who received chemotherapy, according to results of a phase 3 clinical trial published in …